Increased biologic utilization in Latino patients with psoriasis

摘要

Introduction Hispanic/Latino populations are more likely to have extensive psoriasis than the non-Hispanic/Latino population. Biologics are indicated for moderate/severe psoriasis or psoriasis with comorbidities. No studies have assessed ethnicity as a predictor of biologic utilization. We aimed to determine if biologic utilization differs between Latinos and non-Latinos with psoriasis. Methods This study utilizes data from the National Ambulatory Medical Care Survey (NAMCS) from 2003 to 2016. Psoriasis visits were selected by International Classification of Diseases, Ninth or Tenth Revision (ICD-9/ICD-10) classification. The primary outcome is biologic use at the time of visit. Results Of 1202 psoriasis visits, Latinos consisted of 9.7 (95 Confidence Interval 7.3-12) of the study population and 65 (95CI 61-69) used private insurance. Multivariate analysis reveals the increased likelihood of biologic utilization in Latinos compared to non-Latinos (Odds Ratio (OR) 2.4, 95 CI 1.1-5.4,p = .03). Independently, private insurance status is associated with increased biologic use compared to public insurance (OR 2.4, 95 CI 1.2-5.0,p = .02). Private insurance status did not differ between Latinos and non-Latinos with psoriasis (OR 1.0, 95 CI 0.5-1.9,p = .98). Conclusions Hispanic/Latino ethnicity and private insurance status are independent predictors of biologic utilization, suggesting that biologic mechanisms may influence the increased use of biologics in Latinos with psoriasis.